Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0697

-0.4%

Nov 24 3:55 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: boomertree2	10/3/2012 8:30:45 AM
	of 13111

Drug Meets Progression-Free Survival Goal In Melanoma Trial. Reuters (10/3, Sridharan) reports Celgene Corp. announced Tuesday that in a Phase III clinical trial on its drug Abraxane (paclitaxel protein-bound particles for injectable suspension [albumin-bound]) in chemotherapy-naive patients with metastatic melanoma, the participants who were administered Abraxane had a significant improvement in progression-free survival compared to the patients who received dacarbazine chemotherapy. The Boundry, Switzerland-based company said progression-free survival was the primary endpoint. But Celgene did not provide other details from the late-stage trial. At present, Abraxane is approved for treatment-resistant breast cancer; and Celgene said is it planning to seek approval to market the drug as a pancreatic cancer treatment.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next